WINT (Windtree Therapeutics) Accounts Payable & Accrued Expense: $3.66 Mil (As of Sep. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Windtree Therapeutics Accounts Payable & Accrued Expense?

Windtree Therapeutics WINT Accounts Payable & Accrued Expense is $3.66 Mil as of Sep. 2025. The stock has 2 warning signs investors should review.

Windtree Therapeutics's quarterly accounts payable & accrued expense increased from Mar. 2025 ($4.90 Mil) to Jun. 2025 ($6.93 Mil) but then declined from Jun. 2025 ($6.93 Mil) to Sep. 2025 ($3.66 Mil).

Windtree Therapeutics's annual accounts payable & accrued expense increased from Dec. 2022 ($1.80 Mil) to Dec. 2023 ($2.43 Mil) and increased from Dec. 2023 ($2.43 Mil) to Dec. 2024 ($3.59 Mil).

Windtree Therapeutics Accounts Payable & Accrued Expense Historical Data

* Premium members only.

The historical data trend for Windtree Therapeutics's Accounts Payable & Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Windtree Therapeutics Accounts Payable & Accrued Expense Chart

Windtree Therapeutics Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Accounts Payable & Accrued Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4.97 4.10 1.80 2.43 3.59

Windtree Therapeutics Quarterly Data
Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25
Accounts Payable & Accrued Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.70 3.59 4.90 6.93 3.66

Windtree Therapeutics Accounts Payable & Accrued Expense Calculation

Accounts payable & accrued expense usually includes accounts payable, accrued compensation and related benefits, etc.

Accounts payable is money owed by a business to its suppliers shown as a liability on a company's balance sheet. It is distinct from notes payable liabilities, which are debts created by formal legal instrument documents.

It is part of the current portion of the liabilities (due within one year or within the normal operating cycle if longer) reflected on the balace sheet of the company. A higher Accounts Payable means lower Working Capital needed to operate the business.

What does a Accounts Payable & Accrued Expense of $3.66 Mil mean?
Windtree Therapeutics (WINT) has a Accounts Payable & Accrued Expense of $3.66 Mil as of Sep. 2025. Accounts payable and accrued expenses are amounts a company expects to pay to suppliers and others. View historical data on Windtree Therapeutics and its competitors.
Is Windtree Therapeutics' Accounts Payable & Accrued Expense too high?
Windtree Therapeutics' current Accounts Payable & Accrued Expense is $3.66 Mil.
How does Windtree Therapeutics' Accounts Payable & Accrued Expense compare to LIPO and ITRMF?
Windtree Therapeutics' Accounts Payable & Accrued Expense of $3.66 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Accounts Payable & Accrued Expense for a Biotechnology company?
A good Accounts Payable & Accrued Expense depends on the Biotechnology industry context. However, Accounts Payable & Accrued Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Accounts Payable & Accrued Expense mean?
A high Accounts Payable & Accrued Expense can signal that a stock is expensive relative to its fundamentals. Accounts payable and accrued expenses are amounts a company expects to pay to suppliers and others. View historical data on Windtree Therapeutics and its competitors. Windtree Therapeutics's current Accounts Payable & Accrued Expense is $3.66 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Windtree Therapeutics stock overvalued right now?
Windtree Therapeutics (WINT) has a current Accounts Payable & Accrued Expense of $3.66 Mil. The current Accounts Payable & Accrued Expense is $3.66 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Accounts Payable & Accrued Expense calculated?
Accounts Payable & Accrued Expense is calculated from a company's financial statements. For Windtree Therapeutics (WINT), the current Accounts Payable & Accrued Expense is $3.66 Mil as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Windtree Therapeutics Business Description

Address 2600 Kelly Road, Suite 100, Warrington, PA, USA, 18976-3622
Windtree Therapeutics Inc is a biotechnology company focused on advancing early and late-stage therapies for critical conditions and diseases. Its portfolio of product candidates includes istaroxime, a Phase 2 candidate with sarco endoplasmic reticulum Ca2+ -ATPase 2a, or SERCA2a, activating properties for acute heart failure and associated cardiogenic shock, preclinical SERCA2a activators for heart failure, rostafuroxin for the treatment of hypertension in patients with a specific genetic profile, and a preclinical atypical protein kinase C iota, or aPKCi, inhibitor, being developed for potential application in rare and broad oncology indications. It operates in one operating segment, which is the research and development of products focused on cardiovascular disease.